In conclusion, the outcomes of this study suggest that anti-PD-L1 antibody has anti-tumor effect on metastatic brain tumor, and that regimens containing anti-PD-L1 antibody may be promising therapeutic options for patients with brain metastases. This evidence concerns the gene CD274 and neoplasm.